BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced that in the most recent issue of the medical journal, Circulation, an independent team of medical researchers from Germany and the U.S. published new and expanded data showing that administration of thymosin beta 4 (Tß4) significantly decreased heart damage after cardiac ischemia and reperfusion in pigs. In this study, the animals underwent LAD occlusion (blockage of coronary artery) for 60 minutes to simulate a heart attack and were then reperfused (opening of coronary artery) to simulate the standard of care for AMI (heart attack) patients. Tß4 or a placebo was then infused directly into the damaged area. Tß4 significantly decreased cardiac tissue damage, enhanced function of the damaged heart tissue, and reduced MPO levels (an enzyme associated with inflammation and adverse outcomes in patients with acute coronary syndrome) when compared to placebo.
